Cyclome 250 Capsule contains Cycloserine (250 mg), an effective second-line anti-tubercular agent used in the management of multi-drug resistant tuberculosis (MDR-TB). Cycloserine works by inhibiting bacterial cell wall synthesis, thereby controlling the growth of Mycobacterium tuberculosis.
It is typically prescribed as part of a combination therapy regimen for patients who do not respond to first-line anti-TB drugs. Regular monitoring is essential due to its neurotoxic potential, but its efficacy in resistant TB cases makes it a critical medicine.
Belonging to the anti-infective and tuberculosis segment, Cyclome 250 Capsule is in high demand in hospitals, clinics, and government TB programs. Its inclusion in MDR-TB treatment protocols ensures recurring demand in the healthcare sector.
For PCD pharma franchise partners, third-party manufacturers, and exporters, Cyclome 250 Capsule represents a profitable B2B opportunity. Its specialized therapeutic use guarantees strong market potential and long-term business sustainability across India.
Common side effects may include headache, dizziness, nausea, vomiting, and mild peripheral neuropathy. Rarely, severe neurological symptoms, seizures, or psychiatric effects may occur. Report any unusual neurological or psychiatric symptoms to your doctor immediately.
Cyclome 250 Capsule is indicated for the treatment of multidrug-resistant tuberculosis (MDR-TB), usually as part of a combination therapy regimen. It helps control the infection and prevents the spread of TB bacteria.
Take Cyclome 250 Capsule exactly as prescribed, usually on an empty stomach for better absorption. Regular monitoring of liver function, kidney function, and neurological status is essential during therapy. Inform your doctor if you have a history of epilepsy, kidney disease, or psychiatric disorders.
Store Cyclome 250 Capsule in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children.